Cheung N Wah, Conn Jennifer J, d'Emden Michael C, Gunton Jenny E, Jenkins Alicia J, Ross Glynis P, Sinha Ashim K, Andrikopoulos Sofianos, Colagiuri Stephen, Twigg Stephen M
Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, NSW, Australia.
Med J Aust. 2009 Sep 21;191(6):339-44. doi: 10.5694/j.1326-5377.2009.tb02819.x.
Tight glycaemic control reduces the risk of development and progression of organ complications in people with type 1 or type 2 diabetes. In this position statement, the Australian Diabetes Society recommends a general target glycated haemoglobin (HbA(1c)) level of </= 7.0% for most patients. This position statement also provides guidelines for the individualisation of glycaemic targets to a tighter or lesser degree, with a recommended target HbA(1c) level of </= 6.0% in some people, or up to </= 8.0% in others. Individualisation of the HbA(1c) target is based on patient-specific factors, such as the type of diabetes and its duration, pregnancy, diabetes medication being taken, presence of cardiovascular disease, risk of and problems from hypoglycaemia, and comorbidities. Management of diabetes also includes: adequate control of other cardiovascular risk factors, including weight, blood pressure and lipid serum levels; antiplatelet therapy; and smoking cessation.
严格控制血糖可降低1型或2型糖尿病患者发生器官并发症及病情进展的风险。在本立场声明中,澳大利亚糖尿病协会建议大多数患者糖化血红蛋白(HbA₁c)的总体目标水平≤7.0%。本立场声明还提供了血糖目标个体化的指导原则,即目标可更严格或稍宽松,建议部分患者的HbA₁c目标水平≤6.0%,另一些患者则最高≤8.0%。HbA₁c目标的个体化基于患者的特定因素,如糖尿病类型及其病程、妊娠、正在服用的糖尿病药物、心血管疾病的存在、低血糖风险及相关问题,以及合并症。糖尿病管理还包括:充分控制其他心血管危险因素,包括体重、血压和血脂水平;抗血小板治疗;以及戒烟。